NCT07478575Active, not recruiting
Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure
Effects of SGLT2 Inhibitors on Erythropoiesis and Associated Cardio-Renal Outcomes in Heart Failure Patients: A Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
This retrospective cohort study investigates the effects of SGLT2 inhibitor therapy on erythropoiesis and its association with cardiac and renal outcomes in patients with chronic heart failure. The study will compare hematological parameters, echocardiographic measures, and clinical outcomes between patients who initiated SGLT2 inhibitor therapy and a matched control group receiving guideline-directed medical therapy alone over a 12-month follow-up period.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 85 (estimated)
- First submitted
- 12 Mar 2026
- Start date
- 1 Jan 2019
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University Medical Centre Ljubljana
- Diseases
- Heart failure
- NCT number
- NCT07478575
What you commit to
- Study type: Observational
- Planned participants: 85
- From 1 Jan 2019 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute cardiac event within 3 months prior to baseline
Other illness
- Active malignancy or hematological disease affecting erythropoiesis
- Known allergy to any SGLT2 inhibitor component
Lab values
- Severe renal insufficiency (eGFR \<15 mL/min/1.73m²)
- Severe liver insufficiency (AST/ALT \>3× upper limit of normal, bilirubin \>2× upper limit of normal)
Other
- Incomplete or missing data in electronic medical records
- Use of erythropoiesis-stimulating agents or regular erythrocyte transfusions during the observation period
- Pregnancy or breastfeeding
Who the study is looking for
- Diagnosis of chronic heart failure
- Receiving guideline-directed medical therapy for heart failure for at least 3 months prior to inclusion
- Age ≥18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Centre Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.